



DR LESLEY SEYMOUR

Director of the Investigational New Drug Program, and Compliance, Deputy Director of the Canadian Clinical Trials Group, Professor of Oncology at Queens University, Kingston Ontario.

La nouvelle nomenclature d'évaluation tumorale iRECIST (Response Evaluation Criteria in Solid Tumours)

A description of the rationale and purpose for the development of iRECIST, as well as an outline of the key principles of the guidelines, will be provided. The conference will also include; practical examples, discussion of real and potential issues, questions sessions.

Cette conférence sera présentée en anglais.

Le 27 février 2018 de 14h30 à 16h00

CENTRE DE RECHERCHE DU CHUM

Pavillon R
900, rue Saint-Denis
5^e étage, Salle R05.220

L'AUDACE DE
CHERCHER
PLUS LOIN
